ZBH Stock Cash Flow Statements

Zimmer Biomet Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Zimmer Biomet Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2010-12-31	2009-12-31

cash flows from operating activities:
net earnings	153,400,000	182,600,000		249,200,000	243,100,000	172,800,000									-83,900,000	145,800,000	142,500,000	197,700,000	333,800,000	246,100,000	-208,200,000	-509,100,000	321,400,000	432,000,000	131,900,000	246,200,000	-902,500,000	162,100,000	184,900,000	176,200,000	1,231,200,000	299,300,000	69,700,000	157,900,000	-28,800,000	105,800,000	126,700,000	900,000	-158,200,000	176,800,000	156,500,000	165,300,000	176,100,000	221,100,000	235,400,000	154,100,000	151,700,000	218,000,000	152,300,000	177,700,000	214,000,000	208,900,000	156,100,000
adjustments to reconcile net earnings to cash from operating activities:
depreciation and amortization	271,800,000	254,400,000	263,600,000	250,900,000	243,200,000	238,600,000	241,200,000	241,200,000	237,500,000	231,800,000	228,500,000	231,400,000	232,700,000	233,800,000	267,100,000	265,100,000	266,500,000	268,700,000	265,400,000	258,600,000	255,700,000	253,000,000	253,900,000	251,500,000	253,000,000	247,700,000	254,800,000	260,600,000	261,600,000	263,500,000	264,500,000	267,600,000	252,000,000	288,100,000	252,300,000	246,900,000	284,300,000	239,500,000	99,600,000	89,000,000	92,600,000	90,900,000	91,300,000	101,000,000	90,100,000	91,900,000	91,400,000	85,100,000	90,200,000	82,700,000	93,400,000	96,800,000	94,300,000	90,700,000	87,800,000
share-based compensation	21,200,000	19,600,000	21,100,000	24,500,000	26,400,000	29,000,000	25,300,000	15,600,000	33,900,000	25,000,000	26,800,000	27,400,000	27,600,000	23,200,000	17,700,000	21,200,000	24,800,000	21,600,000	17,700,000	23,700,000	21,800,000	16,500,000	22,700,000	21,600,000	19,700,000	20,300,000	20,200,000	19,300,000	12,100,000	13,900,000	13,600,000	14,000,000	11,400,000	15,200,000	18,000,000	12,700,000	11,700,000	13,500,000	8,300,000	12,900,000	12,400,000	12,800,000	13,000,000	11,200,000	11,400,000	10,900,000	12,200,000	14,000,000	13,300,000	13,900,000	15,000,000	12,800,000	14,400,000	16,600,000	17,600,000
changes in operating assets and liabilities, net of acquired assets and liabilities
income taxes	-116,400,000	-15,600,000	22,600,000	-76,700,000	-95,900,000	-8,600,000	-97,200,000	9,600,000	-7,700,000	21,500,000	-140,500,000	-25,400,000	15,500,000	-2,500,000	-48,400,000	-37,500,000	-27,800,000	-9,500,000	-236,100,000	-8,900,000	-700,000	-45,400,000	467,700,000	-312,100,000	-68,700,000	24,500,000	-92,500,000	-15,900,000	-51,000,000	8,600,000	395,600,000	-86,900,000	141,300,000	-165,800,000	54,400,000	-40,800,000	133,400,000	-600,000	43,800,000	-13,300,000		-19,900,000	-38,800,000	-75,600,000		-2,400,000	-65,400,000	17,600,000		19,100,000	-37,200,000	47,800,000
receivables	200,000	-18,800,000	-49,600,000	-29,900,000	12,500,000	-22,700,000	-67,400,000	7,500,000	-600,000	8,600,000	-70,200,000	-32,700,000	-67,600,000	-14,200,000	-33,000,000	12,600,000	-38,300,000	43,600,000	-83,600,000	-259,100,000	-17,000,000	289,700,000	-203,300,000	80,200,000	-21,400,000	50,700,000	-23,800,000	59,700,000	31,500,000	146,200,000	-173,200,000	26,800,000	-57,500,000	40,500,000	-37,400,000	-83,400,000	-85,500,000	88,700,000	-65,900,000	6,600,000	1,900,000	-27,600,000	-20,000,000	5,300,000	-41,300,000	57,000,000	-45,800,000	-44,200,000	-11,300,000	52,700,000	-32,700,000	-54,200,000	-23,500,000	-19,900,000	-15,500,000
inventories	-37,200,000	-3,000,000	87,900,000	3,800,000	13,500,000	-55,300,000	-28,200,000	-64,200,000	-53,800,000	-94,200,000	-12,100,000	-37,100,000	-25,800,000	-600,000	113,400,000	-200,000	-8,300,000	-86,100,000	67,800,000	14,000,000	-26,600,000	-96,000,000	-19,200,000	-23,000,000	-32,300,000	-50,700,000	-34,300,000	-65,900,000	-59,600,000	-39,700,000	400,000	-11,500,000	32,200,000	-16,000,000	21,900,000	38,300,000	-8,900,000	-46,600,000	-87,700,000	-62,200,000	-19,900,000	-49,000,000	-28,600,000	-56,600,000	-13,300,000	-28,900,000	-26,500,000	-59,700,000	-14,200,000	-23,600,000	-23,700,000	-6,000,000	34,900,000	18,900,000	58,500,000
accounts payable and accrued liabilities	76,800,000	-36,400,000	-117,300,000	-23,200,000	-62,100,000	-119,400,000	164,200,000	-34,300,000	-93,400,000	-91,800,000	104,600,000	48,300,000	-34,000,000	-15,900,000	83,500,000	49,200,000	104,900,000	-161,200,000	36,300,000	102,500,000	-138,100,000	-95,800,000	120,700,000	107,100,000	-38,400,000	-231,400,000
other assets and liabilities	8,400,000	-100,000	85,500,000	-2,800,000	-11,300,000	-6,400,000	27,200,000	-700,000	22,200,000	-23,500,000	-104,700,000	44,700,000	40,100,000	18,700,000	33,900,000	-23,100,000	-26,700,000	-28,300,000	11,800,000	4,400,000	27,300,000	26,000,000	-1,900,000	20,600,000	-12,900,000	-23,700,000	36,000,000	9,700,000	13,300,000	-50,600,000	148,800,000	-111,500,000	175,700,000	-74,500,000	-25,900,000	-54,100,000	1,900,000	64,100,000	-110,000,000	22,200,000	-4,600,000	71,400,000	-300,000	21,100,000	-55,800,000	14,800,000	23,800,000	-29,900,000	30,300,000	500,000	-13,400,000	-74,800,000	64,400,000	-17,700,000	10,600,000
net cash from operating activities	378,200,000	382,800,000		395,700,000	369,400,000	228,000,000					0	0	7,000,000	-78,500,000	365,700,000	433,100,000	453,900,000	246,500,000	425,100,000	381,300,000	-52,800,000	450,900,000	423,300,000	577,900,000	301,000,000	283,600,000	379,500,000	484,100,000	393,300,000	490,500,000	402,900,000	275,400,000	627,200,000	352,600,000	387,200,000	265,200,000	387,100,000	151,300,000	186,800,000	91,500,000	354,200,000	255,700,000	254,100,000	188,800,000	300,200,000	292,700,000	189,700,000	180,500,000	368,000,000	345,000,000	231,500,000	207,400,000	393,100,000	341,000,000	385,500,000
capex	-50,100,000	-44,600,000		-44,500,000	-52,700,000	-55,100,000					-63,400,000	-47,200,000	-40,900,000	-36,400,000	-63,100,000	-54,200,000	-27,300,000	-27,400,000	-27,700,000	-30,600,000	-19,000,000	-40,200,000	-51,800,000	-58,600,000	-58,900,000	-37,800,000	-47,500,000	-61,500,000	-27,000,000	-26,700,000	-46,200,000	-43,100,000	-54,600,000	-56,400,000	-46,100,000	-27,600,000	-49,100,000	-53,800,000	-30,400,000	-34,400,000	-49,200,000	-32,300,000	-32,000,000	-31,400,000	-22,800,000	-36,900,000	-22,400,000	-17,900,000	-43,300,000	-27,100,000	-24,800,000	-19,500,000	-46,000,000	-38,600,000	-28,300,000
free cash flows	328,100,000	338,200,000		351,200,000	316,700,000	172,900,000					-63,400,000	-47,200,000	-33,900,000	-114,900,000	302,600,000	378,900,000	426,600,000	219,100,000	397,400,000	350,700,000	-71,800,000	410,700,000	371,500,000	519,300,000	242,100,000	245,800,000	332,000,000	422,600,000	366,300,000	463,800,000	356,700,000	232,300,000	572,600,000	296,200,000	341,100,000	237,600,000	338,000,000	97,500,000	156,400,000	57,100,000	305,000,000	223,400,000	222,100,000	157,400,000	277,400,000	255,800,000	167,300,000	162,600,000	324,700,000	317,900,000	206,700,000	187,900,000	347,100,000	302,400,000	357,200,000
cash flows from investing activities:
additions to instruments	-80,500,000	-59,700,000	-51,900,000	-41,200,000	-65,200,000	-82,000,000	-78,900,000	-64,500,000	-85,500,000	-82,800,000	-66,100,000	-71,600,000	-64,200,000	-56,400,000	-78,900,000	-72,400,000	-67,900,000	-82,600,000	-68,900,000	-63,500,000	-73,600,000	-85,700,000	-76,400,000	-94,700,000	-81,100,000	-63,700,000	-72,600,000	-77,600,000	-65,700,000	-60,400,000	-81,300,000	-86,400,000	-94,200,000	-94,000,000	-72,200,000	-85,100,000	-80,400,000	-82,000,000	-41,600,000	-62,400,000	-34,500,000	-50,900,000	-62,600,000	-49,400,000	-26,800,000	-49,800,000	-58,800,000	-57,500,000	-44,200,000	-36,400,000	-39,500,000	-28,800,000	-26,500,000	-59,400,000	-21,000,000
additions to other property, plant and equipment	-50,100,000	-44,600,000	-51,500,000	-44,500,000	-52,700,000	-55,100,000	-62,800,000	-84,300,000	-97,300,000	-46,700,000	-63,400,000	-47,200,000	-40,900,000	-36,400,000	-63,100,000	-54,200,000	-27,300,000	-27,400,000	-27,700,000	-30,600,000	-19,000,000	-40,200,000	-51,800,000	-58,600,000	-58,900,000	-37,800,000	-47,500,000	-61,500,000	-27,000,000	-26,700,000	-46,200,000	-43,100,000	-54,600,000	-56,400,000	-46,100,000	-27,600,000	-49,100,000	-53,800,000	-30,400,000	-34,400,000	-49,200,000	-32,300,000	-32,000,000	-31,400,000	-22,800,000	-36,900,000	-22,400,000	-17,900,000	-43,300,000	-27,100,000	-24,800,000	-19,500,000	-46,000,000	-38,600,000	-28,300,000
net investment hedge settlements	2,500,000	1,000,000	2,800,000	2,800,000	6,300,000	10,200,000	6,200,000	8,200,000	5,600,000	13,400,000	18,200,000	37,300,000	21,200,000	12,700,000	4,300,000	7,200,000	-12,700,000	3,100,000	10,500,000	16,200,000	10,500,000	16,300,000	10,600,000	16,200,000	10,800,000	10,500,000
business combination investments, net of acquired cash			-160,000,000	-49,800,000			-102,000,000	0	-14,000,000	-18,900,000	0	0
acquisition of intangible assets	-30,000,000	-2,400,000	-33,400,000
other investing activities	0	-300,000	2,800,000			-55,600,000	16,800,000	-12,000,000	21,300,000	-14,300,000		-3,700,000	-59,500,000	-1,000,000		-5,800,000												200,000	-900,000	-14,600,000		-3,600,000
net cash from investing activities	-1,384,400,000	-106,000,000		-154,900,000	-247,000,000	-195,000,000					0	0	0	-7,200,000	-146,200,000	-125,200,000	-109,900,000	-122,300,000	-315,900,000	-91,400,000	-85,300,000	-121,200,000	-138,000,000	-163,600,000	-322,200,000	-105,500,000	-82,400,000	-138,900,000	-93,600,000	-101,700,000	-128,200,000	-133,100,000	-146,800,000	-1,374,300,000	-266,200,000	95,800,000	121,500,000	41,300,000	-7,788,600,000	67,900,000	28,700,000	-229,400,000	-170,300,000	-98,400,000	-10,200,000	-150,700,000	-174,600,000	53,000,000	-224,600,000	-85,400,000	-117,900,000	-164,200,000	-213,300,000	-491,500,000	-133,300,000
cash flows from financing activities:
net proceeds from revolving facilities					45,000,000	70,000,000
proceeds from senior notes	0	1,748,100,000	736,300,000																0	0	0	1,497,100,000					0	0	0	749,500,000								0	0	7,628,200,000
redemption of senior notes	0	-863,000,000					0	0	0	-86,300,000	-525,800,000	0	0	-750,000,000	-2,154,800,000	-300,000,000	0	-200,000,000	-250,000,000	0							0				0						0	0
dividends paid to stockholders	-47,500,000	-47,800,000	-48,000,000	-49,200,000	-49,400,000	-49,400,000	-50,200,000	-50,100,000	-50,300,000	-50,300,000	-50,400,000	-50,300,000	-50,300,000	-50,200,000	-50,200,000	-50,100,000	-50,000,000	-49,800,000	-49,800,000	-49,600,000	-49,600,000	-49,500,000	-49,400,000	-49,200,000	-49,100,000	-49,000,000	-49,000,000	-48,800,000	-48,800,000	-48,600,000	-48,600,000	-48,100,000	-48,100,000	-47,900,000	-47,800,000	-44,600,000	-44,800,000	-37,600,000	-37,400,000	-37,300,000	-37,500,000	-37,100,000	-36,900,000	-34,000,000	-34,000,000	-33,900,000	-33,600,000	-30,900,000	-31,200,000	-31,500,000
proceeds from employee stock compensation plans	400,000	16,700,000	500,000	18,600,000	6,600,000	56,400,000	19,300,000	20,700,000	25,100,000	36,000,000	14,900,000	18,200,000	4,500,000	40,500,000	5,200,000	25,800,000	26,200,000	65,300,000	32,100,000	36,000,000	7,200,000	54,500,000	32,300,000	71,100,000	10,400,000	44,400,000	4,500,000	47,000,000	8,500,000	47,900,000	12,900,000	66,100,000	23,100,000	34,900,000	47,300,000	31,300,000	28,200,000	42,400,000	7,100,000	27,500,000	30,200,000	35,600,000	80,700,000	138,200,000	149,400,000	108,700,000	149,700,000	67,000,000	12,800,000	16,100,000	7,700,000	10,300,000	9,400,000	4,000,000	1,900,000
business combination contingent consideration payments	0	-17,400,000	0	-2,000,000	0	-1,500,000	0	0	-700,000	-9,600,000					-2,400,000	0	-700,000	-5,800,000	-2,000,000	-5,500,000	-4,000,000	-3,500,000					-3,100,000	0	-3,100,000	-13,600,000	0	-6,000,000
debt issuance costs	-1,200,000	-16,100,000													-11,700,000				0	-2,900,000	-7,200,000	-12,200,000						0	0	-4,900,000	0		-6,600,000				0	0	0	-58,400,000	0	-16,400,000							0	0
repurchase of common stock	-7,200,000	-229,800,000	-72,200,000	-596,300,000	-85,900,000	-113,600,000	-410,300,000	0	-14,300,000	-267,600,000																							0	0	0	-415,500,000					0	0	0	-400,500,000	-240,700,000	-17,500,000	-68,800,000	-392,000,000	-139,900,000	-97,600,000	-106,500,000	-141,600,000	-143,500,000	-101,000,000	-519,300,000
other financing activities	-900,000	-15,200,000	-3,000,000	-6,900,000	-2,000,000	-10,500,000	700,000	-1,600,000	-100,000	-5,100,000	900,000	-1,900,000	-200,000	-3,300,000	3,300,000	-300,000	-3,800,000	-5,500,000	-1,600,000	-600,000	-100,000	-6,000,000	-4,800,000	-500,000	-700,000	-4,200,000
net cash from financing activities	163,800,000	575,400,000		-101,900,000	-91,900,000	-50,100,000					0	0	0	-68,100,000	-655,800,000	-426,100,000	-28,300,000	-195,800,000	-286,300,000	-42,600,000	-1,585,700,000	1,492,800,000	-182,700,000	-298,400,000	-163,600,000	-135,200,000	-275,500,000	-297,700,000	-1,570,800,000	841,800,000	-232,900,000	256,100,000	-309,100,000	519,200,000	-128,000,000	-825,300,000	-515,800,000	-144,100,000	231,100,000	7,568,600,000	-255,400,000	-15,900,000	-400,000	-290,700,000	-122,200,000	60,300,000	47,100,000	-452,500,000	-58,100,000	-116,300,000	-133,000,000	-129,100,000	37,500,000	-99,000,000	2,200,000
effect of exchange rates on cash and cash equivalents	14,600,000	7,000,000	-18,100,000	10,000,000	-3,300,000	-5,700,000	7,400,000	-3,600,000	-5,800,000	2,900,000	12,000,000	-12,700,000	-12,700,000	-1,100,000	-4,800,000	-4,600,000	2,400,000	-6,200,000	11,900,000	6,600,000	3,600,000	-6,800,000	2,800,000	-6,500,000	1,100,000	1,100,000	-3,400,000	-4,100,000	-13,100,000	10,400,000	1,800,000	7,000,000	-12,500,000	1,500,000	-13,500,000	1,800,000	-400,000	-6,200,000	1,800,000	-17,800,000	-11,500,000	-11,800,000	2,600,000	2,400,000	-4,600,000	5,200,000	-9,300,000	-8,300,000	-2,500,000	7,200,000	-3,600,000	-8,400,000	-2,000,000	-200,000	-2,400,000
change in cash and cash equivalents	-827,700,000	859,100,000		148,900,000	27,100,000	-22,700,000
cash and cash equivalents, beginning of year	0	525,500,000	0	0	0	415,800,000	0	0	0	375,700,000	0	0	0	478,500,000	0	0	0	802,100,000	0	0	0	617,900,000	0	0	0	542,800,000	0	0	0	524,400,000	0	634,100,000	0	0	0	1,459,300,000	0	0	0	1,083,300,000	0	0	0	1,080,600,000	0	0	0	884,300,000	0	0	0	768,300,000	0	0	0
cash and cash equivalents, end of period	-827,600,000	1,384,500,000		148,900,000	27,100,000	393,000,000		-27,700,000	-10,400,000	330,200,000		159,000,000	-49,400,000	435,800,000	-441,100,000	-122,800,000	318,100,000	724,300,000	-165,200,000	253,900,000	-1,720,200,000	2,433,600,000	105,400,000	109,400,000	-183,700,000	586,800,000	18,200,000	43,400,000	-1,284,200,000	1,765,400,000	43,600,000	1,039,500,000	158,800,000	-501,000,000	-20,500,000	996,800,000	-7,600,000	42,300,000	-7,368,900,000	8,793,500,000		-1,400,000	86,000,000	882,700,000		207,500,000	52,900,000	657,000,000		150,500,000	-23,000,000	674,000,000
deferred business combination payments				-1,000,000	-6,300,000	-1,500,000	0	0							-45,000,000
cash flows from operating activities from continuing operations:
net earnings from continuing operations							419,700,000	162,800,000	209,800,000	232,800,000	-130,200,000	194,200,000	154,000,000	73,200,000
adjustments to reconcile net earnings to net cash from operating activities:
goodwill and intangible asset impairment															0	0			0	0							975,900,000				272,000,000
(gain) loss on investment in zimvie inc.							0	0
deferred income tax benefit
net cash from operating activities from continuing operations							588,400,000	337,600,000	347,900,000	307,700,000	244,200,000	450,800,000	345,500,000	315,700,000
cash flows from investing activities from continuing operations:
net cash from investing activities from continuing operations							-220,800,000	-165,600,000	-243,100,000	-149,400,000	-112,500,000	-85,200,000	-243,200,000	-81,100,000
cash flows from financing activities from continuing operations:
net (payments) proceeds on revolving facilities
proceeds from term loan											0																				0		0				0	0
payments on term loans							0				0												-210,000,000	-325,000,000	-115,000,000	-310,000,000
distribution from zimvie, inc.											0	0	0	540,600,000
net cash from financing activities from continuing operations							-251,400,000	-196,000,000	-109,400,000	-206,700,000	-313,400,000	-193,900,000	-146,000,000	-122,400,000
cash flows used in discontinued operations:
net cash from discontinued operations											0	0	7,000,000	-153,800,000
increase in cash and cash equivalents											-169,700,000	159,000,000			-441,100,000	-122,800,000	318,100,000	-77,800,000	-165,200,000	253,900,000	-1,720,200,000	1,815,700,000	105,400,000			44,000,000	18,200,000			1,241,000,000		405,400,000	158,800,000	-501,000,000	-20,500,000	-462,500,000	-7,600,000	42,300,000	-7,368,900,000	7,710,200,000	116,000,000				163,200,000				82,800,000	150,500,000	-23,000,000	-94,300,000	215,300,000	-249,700,000	252,000,000
cash and cash equivalents, end of year
net payments on revolving facilities
payment on term loan									0	-33,900,000
acquisition of intangible assets and other investing activities
acquisition of intellectual property rights						-12,500,000	0	-13,100,000															0	0																														-300,000	-2,900,000
loss on early extinguishment of debt
cash flows from discontinued operations:
adjustments to reconcile net earnings from continuing operations to cash from operating activities from continuing operations:
intangible asset impairment												0												0									2,000,000	0
distribution from zimvie inc.
proceeds from revolving facility									200,000,000	370,000,000		0	120,000,000	100,000,000
payments on revolving facility									-265,000,000	-160,000,000		0
decrease in cash and cash equivalents									-10,400,000	-45,500,000				-42,700,000																													86,000,000	-197,900,000			52,900,000	-227,300,000
(gain) loss on investment in zimvie										-2,500,000
loss on investment in zimvie
investments in other assets																		-15,400,000	6,100,000	-13,500,000	-3,200,000	-11,600,000	16,700,000	-26,500,000	4,600,000	-14,500,000									-12,700,000	-14,700,000	-2,100,000	-10,200,000	-6,400,000	-3,000,000	4,700,000	-7,400,000			66,400,000	-5,500,000	-65,600,000	-8,800,000	39,800,000	-2,100,000	-19,800,000	-34,900,000	23,400,000	-8,900,000	-14,700,000
proceeds from multicurrency revolving facility																											0	0	0	400,000,000	0	400,000,000
payments on multicurrency revolving facility																											0	-25,000,000			0
net cash flows from unremitted collections from factoring programs																			-15,000,000	-20,000,000	-32,000,000	12,400,000	3,200,000	10,200,000	-9,200,000	-16,400,000	17,900,000	8,300,000	-2,100,000	-60,800,000
adjustments to reconcile net earnings from continuing operations to cash from operating activities:
proceeds from term loans																							0	0	0	200,000,000																							0	0
net payments on other debt																							-300,000				0	-3,700,000	0	-200,000
goodwill impairment																						612,000,000
changes in operating assets and liabilities, net of
acquired assets and liabilities
inventory step-up																														100,000	600,000	14,600,000	22,400,000	14,500,000	132,700,000	153,700,000	180,700,000	126,600,000	10,100,000	400,000	400,000	800,000	1,700,000	2,500,000	2,900,000	2,700,000	1,600,000	800,000		500,000	1,000,000	1,000,000	1,800,000	100,000	2,600,000
debt extinguishment
purchases of investments																																	-100,000	-200,000	-900,000	-300,000	-35,800,000	-26,400,000	0	-152,600,000	-200,800,000	-366,800,000	-182,600,000	-600,700,000	-152,400,000	-214,300,000	-271,200,000	-94,800,000	-328,400,000	-264,200,000	-281,900,000	-255,600,000	-258,300,000	-312,700,000
sales of investments																																	12,900,000	0	49,800,000	223,500,000	224,100,000	179,900,000	78,600,000	320,300,000	362,800,000	228,000,000	108,300,000	583,100,000	199,600,000	155,800,000	243,400,000	232,000,000	211,400,000	244,400,000	248,100,000	174,600,000	169,800,000	11,000,000
ldr acquisition, net of acquired cash																																	0
changes in operating assets and liabilities, net of effect of acquisitions:
accounts payable and accrued expenses																												50,700,000	600,000	-27,700,000		-137,000,000		65,900,000	-21,200,000	-120,700,000		-347,300,000	245,300,000	-149,500,000		8,200,000	54,300,000	-56,000,000		-12,500,000	40,100,000	-31,300,000		19,700,000	14,200,000	-29,900,000
cash flows used in investing activities:
other business combination investments, net of acquired cash																																		-237,800,000
payments on term loan																												-275,000,000	0	-225,000,000	-300,000,000	-150,000,000	-100,000,000	-200,000,000	-100,000,000	-400,000,000	-350,000,000
restricted stock withholdings																												-500,000	-300,000	-2,500,000	-700,000
payments on senior notes
biomet merger consideration compensation expense
excess income tax benefit from stock option exercises																																				-3,200,000	-1,500,000	-1,200,000	-1,300,000	-7,800,000	-1,400,000	-1,100,000	-3,200,000	-5,400,000	-1,300,000	-2,200,000	-1,600,000	-3,500,000	-400,000	-900,000	-200,000	-1,200,000	-1,000,000	-200,000	-300,000
gain on divestiture of assets																																					-10,100,000	10,000,000
deferred income tax provision
proceeds from divestiture of assets																																					12,000,000	33,800,000
biomet acquisition, net of acquired cash																																						0
net (payments) proceeds on other debt																																-700,000
unremitted collections from factoring programs
restricted stock witholdings																																-5,200,000		-100,000
proceeds from (payments on) senior notes
net proceeds (payments) under revolving credit facilities																																																	99,800,000
income tax benefit from stock option exercises																																				10,000,000	3,700,000	3,700,000	57,600,000	16,400,000	4,500,000	3,900,000	8,600,000	20,200,000	9,300,000	7,300,000	8,200,000	13,600,000	1,000,000	2,700,000	1,100,000	6,200,000	2,300,000	800,000	2,800,000
non-cash biomet merger consideration compensation expense																																						0
loss on divestiture of assets
net proceeds (payments on) under revolving credit facilities
net proceeds under revolving credit facilities																																				300,000		-100,000	100,000	800,000											-146,700,000	1,000,000
biomet acquistion, net of acquired cash
business combination investments
income taxes payable
payment of senior notes
equity issuance costs
purchase of additional shares from noncontrolling interest																																													0	0
net payments under revolving credit facilities																																										900,000	300,000	200,000		800,000
proceeds from issuance of notes
net (payments) proceeds under revolving credit facilities																																																-100,100,000
inventory step-up and other inventory charges
other business combination investments
net curtailment and settlement																																																							0
acquisition of noncontrolling interest																																																							0
net earnings of zimmer holdings, inc.																																																						34,900,000	155,200,000
gain on sale of investments
in-process research and development
changes in operating assets and liabilities, net of acquired assets and liabilities income taxes payable
abbott spine acquisition, net of acquired cash
net borrowing under credit facilities
purchases of short-term investments
sales of short-term investments
purchases of certificates of deposit
sales of certificates of deposit
adjustments to reconcile net earnings to net cash provided
by operating activities:
proceeds from sale of investments
net proceeds (payments) under revolving credit facility
changes in operating assets and liabilities:
proceeds from sale of property, plant and equipment
other acquisitions, net of acquired cash
net borrowings under credit facilities
effect of exchange rates on cash and equivalents
increase in cash and equivalents
cash and equivalents, beginning of year
cash and equivalents, end of year
zimmer holdings, inc.
gain on sale of other assets
proceeds from sale of other assets
acquisitions, net of acquired cash
cash and equivalents, end of period
1.
net proceeds (payments) on lines of credit
for the years ended december 31,
other comprehensive income
foreign currency cumulative translation adjustments
unrealized foreign currency hedge gains/(losses), net of tax effects of 11.5 in 2007, 7.6 in 2006 and (17.8) in 2005
reclassification adjustments on foreign currency hedges, net of tax effects of (1.3) in 2007, (1.8) in 2006 and (12.7) in 2005
unrealized gains/(losses) on securities, net of tax effects of 0.9 in 2007, 0.9 in 2006 and 0.9 in 2005
prior service cost and unrecognized (gain)/loss in actuarial assumptions, net of tax effects of (0.4) in 2007
minimum pension liability adjustment, net of tax effects of (0.6) in 2006
comprehensive income
net proceeds on lines of credit
cash flows from (used in) operating activities:
cash flows from (used in) investing activities:
cash flows from (used in) financing activities:
share-based payment expense
centerpulse and incentive acquisitions, net of acquired cash
implex acquisition, net of acquired cash
proceeds from note receivable
other
zimmer holdings, inc. and subsidiaries
changes in operating assets and liabilities, net of acquired assets and liabilities:
proceeds from exercise of stock options
net payments on lines of credit
decrease in cash and equivalents
net earnings, as reported
deduct: total stock-based compensation expense determined under fair value based method for all awards, net of tax
pro forma net earnings
earnings per share:
basic — as reported
basic — pro forma
diluted — as reported
diluted — pro forma
changes in operating assets and liabilities, net of acquisitions:
basic - as reported
basic - pro forma
diluted - as reported
diluted - pro forma

We provide you with 20 years of cash flow statements for Zimmer Biomet stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Zimmer Biomet stock. Explore the full financial landscape of Zimmer Biomet stock with our expertly curated income statements.

The information provided in this report about Zimmer Biomet stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.